CDK4/6 inhibitor abemaciclib induces atypical cell-death with vacuolar formation by impairing lysosomal functions

被引：0
|
作者：
Hino, Hirotsugu [1 ]
Kazama, Hiromi [2 ]
Moriya, Shota [2 ]
Takano, Naoharu [2 ]
Hiramoto, Masaki [2 ]
Miyazawa, Keisuke [2 ]
机构：
[1] Nihon Univ, Div Anat Sci, Dept Funct Morpho, Sch Med, Tokyo, Japan
[2] Tokyo Med Univ, Dept Biochem, Tokyo, Japan
来源：
CANCER SCIENCE | 2021年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PJ16-4-3
引用
收藏
页码：900 / 900
页数：1
相关论文
共 50 条
  • [21] The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade
    Dempsey, Jack
    Huber, Lysiane
    Forest, Amelie
    Stephens, Jennifer R.
    Doman, Thompson N.
    Manro, Jason
    Capen, Andrew
    Flack, Robert S.
    Donoho, Gregory P.
    Buchanan, Sean
    De Dios, Alfonso
    Driscoll, Kyla
    Kalos, Michael
    Novosiadly, Ruslan
    Beckmann, Richard P.
    Schaer, David A.
    CANCER RESEARCH, 2017, 77
  • [22] An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum
    Habler, Katharina
    Vogeser, Michael
    Teupser, Daniel
    JOURNAL OF MASS SPECTROMETRY AND ADVANCES IN THE CLINICAL LAB, 2022, 24 : 15 - 21
  • [23] CDK4 & 6 inhibitor Abemaciclib exerts intrinsic immunomodulatory effects on human T cells in vitro
    Chin, Darin
    Carpenito, Carmine
    Amaladas, Nelusha
    Chung, Linda
    Staschke, Kirk
    Schaer, David
    Beckmann, Richard
    Novosiadly, Ruslan
    Kalos, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [24] Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer In Vitro and In Vivo
    Naz, Sarwat
    Sowers, Anastasia
    Choudhuri, Rajani
    Wissler, Maria
    Gamson, Janet
    Mathias, Askale
    Cook, John A.
    Mitchell, James B.
    CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3994 - 4005
  • [25] CDK4/6 Inhibition With Abemaciclib in Patients With Previously Treated Advanced Renal Cell Carcinoma
    Mcgregor, Bradley A.
    Xie, Wanling
    Berg, Stephanie A.
    Xu, Wenxin
    Viswanathan, Srinivas R.
    Mcdermott, David
    Signoretti, Sabina
    Kaelin, William G.
    Choueiri, Toni K.
    CLINICAL GENITOURINARY CANCER, 2025, 23 (03)
  • [26] Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Morschhauser, Franck
    Bouabdallah, Kamal
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    Wolf, Martin
    de Guibert, Sophie
    Zettl, Florian
    Hahka-Kemppinen, Marjo
    Wang, David Xiaohui
    Brueck, Patrick
    Caldwell, Charles
    Beckmann, Richard
    Gelbert, Lawrence
    Cronier, Damien
    Lin, Ji
    Li, Lily
    Chan, Edward M.
    Pfreundschuh, Michael
    Wilhem, Martin
    Hess, Georg
    BLOOD, 2014, 124 (21)
  • [27] CDK4/6 inhibitor abemaciclib has been established in early as well as locally advanced and metastatic settings
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (04) : 156 - 157
  • [28] Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
    Sun, Chao-Yue
    Talukder, Milton
    Cao, Di
    Chen, Cun-Wu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [29] Preclinical selectivity profile of the CDK4/6 inhibitor ribociclib (LEE011) compared with that of palbociclib and abemaciclib
    Tiedt, Ralph
    Delach, Scott
    Kovats, Steven
    Horn, Thomas
    Acker, Michael
    Engstler, Barbara Schacher
    Caponigro, Giordano
    Su, Fei
    CANCER RESEARCH, 2017, 77
  • [30] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
12345